Hetero has launched its generic semaglutide portfolio in overseas markets even as it is awaiting regulatory approvals in India. The launch represents the beginning of a strategic, multi-year global ...

Two-time cancer survivor Sherman McDaniel may be in fragile health, but she is sticking to her vow: “I’m not going anywhere until Generic Theater has a permanent home. Until then, I will not die.” ...

All the Indian generics are substantially cheaper – the prices vary between Rs 1,300 and Rs 4,500 per month - than the original ones.

Did our AI summary help? Hetero has begun exporting generic versions of semaglutide, accelerating competition in the global market for diabetes and obesity medicines as demand for GLP‑1 therapies ...

US slaps 100% tariffs on patented drugs Tariff exemption for generics shields most Indian drugmakers Sun Pharma faces capped 15% tariffs on innovative products. Did our AI summary help? Indian ...

The proposed 100% tariff on patented drugs in the United States is expected to significantly impact the global pharmaceutical sector. This move could increase the prices of patented medicines, ...

Danish pharma giant Novo Nordisk has once again reduced the prices of its blockbuster drugs Ozempic and Wegovy in India. The strategic move is aimed at staying ahead of the entry of the low-cost ...

Danish pharmaceutical giant Novo Nordisk on Tuesday announced price cuts of up to 48% on its blockbuster diabetes and obesity drugs Ozempic and Wegovy in India, weeks after semaglutide—the active ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Following its FDA approval in the summer, Tonix Pharma's fibromyalgia therapy Tonmya has been launched onto the market in the US, becoming the first new drug for the painful condition in more than 16 ...